BBOT’s ON/OFF Biology: A Game-Changer in Oncology

BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) unveiled promising updates across its oncology pipeline, solidifying its position as a leader in innovative cancer therapies. The standout is BBO-8520, which continues to demonstrate its potential as the best-in-class KRASG12C inhibitor, thanks to its unique ON/OFF binding mechanism. This approach enables broader target coverage with reduced toxicity, a significant advantage over traditional OFF-only inhibitors.

BBO-8520: Leading the KRASG12C Race

Updated ONKORAS-101 data revealed a 65% overall response rate (ORR) and 66% six-month progression-free survival (PFS) in KRAS G12C non-small cell lung cancer (NSCLC). Impressively, 83% of patients remained on therapy beyond six months. The ON/OFF mechanism allows for lower drug exposure, reducing liver toxicity and avoiding dose reductions in PD-1 combinations, positioning 8520 as a strong contender for first-line treatment.

BBO-11818: Pan-KRAS Progress

BBO-11818 achieved a confirmed partial response in a heavily pretreated pancreatic cancer patient, with a 56% tumor reduction. Activity was observed across dose levels and tumor types, with 600 mg BID showing coverage of G12D and G12V alleles. Manageable safety data further de-risks BBOT’s pan-KRAS strategy as it moves toward expansion and combination studies.

BBO-10203: Breaking New Ground

The novel RAS-PI3Kα dimer-breaker, BBO-10203, completed Phase 1a dose escalation in the BREAKER-101 trial. The drug demonstrated activity across dose levels with complete target engagement at steady state. The recommended dose of 500 mg QD showed no idiosyncratic toxicity, including the absence of hyperglycemia, even in heavily pretreated patients. This safety profile could be a key differentiator in future combination therapies.

Looking Ahead to 2026

BBOT plans to release additional monotherapy and combination data for BBO-8520 and BBO-11818 in the second half of 2026. Combination studies for BBO-10203 are also slated to begin, targeting HER2+ breast cancer, HR+/HER2- PIK3CA-mutant breast cancer, and KRAS-mutant colorectal cancer. These updates reinforce BBOT’s innovative approach and its potential to reshape oncology treatment paradigms.

With a robust pipeline and groundbreaking mechanisms, BBOT remains a company to watch in 2026.

For more information please visit www.bbotx.com .